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Summary
 
Objective
 
The polymorphic deletion of exon 3 of the GH receptor
(d3-GHR) has recently been linked to the magnitude of growth
response to recombinant human GH (rhGH) therapy in short chil-
dren with or without GH deficiency. We investigated this association
in a large multinational cohort from the Network of European Studies
of Genes in Growth (NESTEGG), comprising short children born
small for gestational age (SGA).
 
Design
 
The study included short prepubertal SGA children treated
with rhGH for 1 or 2 years.
 
Population
 
Two hundred and forty white Caucasian SGA children
(138 male, 102 female) aged 6·6 ± 2·3 years with a height at –3·0 ± 0·7
SDS at start of rhGH treatment; 193 ethnically matched controls.
 
Methods
 
The GHR polymorphism (fl/fl, fl/d3 or d3/d3) was geno-
typed by polymerase chain reaction (PCR) multiplex assay. Growth
velocity (G/V) in cm/year and changes in GV during the first and
second year of rhGH treatment were evaluated.
 
Results
 
The change in GV was significantly greater in SGA children
carrying one or two copies of the d3-GHR allele (
 
P = 
 
0·038 for the
first year and 
 
P
 
 = 0·041 for the second year of GH treatment), but
the change in height was not significantly different. Birthweight was
significantly lower in SGA children with the d3/d3 genotype than in
SGA children with the fl/fl genotype (
 
P = 
 
0·034) and in those with
the fl/d3 genotype (
 
P = 
 
0·016).
 
Conclusion
 
Our data, based on a large cohort, showed that the
exon 3 GHR polymorphism is associated with responsiveness to
rhGH treatment in SGA children with short stature.
(Received 4 January 2007; returned for revision 9 February 2007; 
 
finally revised 23 March 2007; accepted 30 March 2007)
 
Introduction
 
Response to recombinant human growth hormone (rhGH) therapy
in short children without GH deficiency is variable
 
1,2
 
 and the
prediction of this response may not be accurate. Prediction models
based on variables such as age, weight, parental height and rhGH
dosage only explain half of the response to rhGH, suggesting the
existence of genetic and environmental determinants still unknown.
 
3
 
GH acts at the target cell through the GH receptor, which, after binding
of the ligand, stimulates a signalling cascade that leads to target genes
transcription. This receptor contains an unusual genetic polymor-
phism caused by a genomic deletion of exon 3 (d3-GHR) that mimics
alternative splicing.
 
4
 
 This deletion results in the loss of amino acid
residues 7–28 and the amino acid substitution A6D at the N-terminal
part of the extracellular domain, although the deleted protein does
not have altered affinity for GH.
 
5
 
 It has been demonstrated, in trans-
fection experiments, that the transduction of GH signalling through
d3-GHR homo- or heterodimers was almost 30% higher than
through the full-length GHR homodimer.
 
6
 
 These data corroborate
the association of the d3-GHR variant with increased responsiveness
to rhGH in short children without GH deficiency. The children
genotyped in this first report consisted of short children born small
for gestational age (SGA) (
 
n
 
 = 60) and with idiopathic short stature
(
 
n
 
 = 112).
 
6
 
 Another publication has confirmed the increased rhGH
responsiveness in Turner syndrome (
 
n
 
 = 53) and SGA (
 
n
 
 = 60),
 
7
 
 but
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a recent study of short children born SGA did not confirm these
data.
 
8
 
 We have investigated this association in the cohort from the
Network of European Studies of Genes in Growth (NESTEGG),
 
9
 
consisting of children from four different countries (France, the
Netherlands, the UK and Germany).
 
Subjects and methods
 
Patients
 
The NESTEGG project, which had been approved in all countries
by their own ethical committees, recruited children born SGA,
children with idiopathic short stature and controls across four
different countries (France, the Netherlands, the UK and Germany)
according to a standard protocol where detailed phenotypic features
were recorded and blood sampling was undertaken to provide DNA.
 
9
 
Prepubertal white Caucasian SGA children (
 
n
 
 = 240) with short
stature (height SDS 
 
≤
 
 –1·88 and/or weight SDS 
 
≤
 
 –1·88) treated with
rhGH for at least 1 year were included in the present analysis.
We chose the cut-off of –1·88 instead of –2 SDS to avoid the exclusion
of some borderline children. Exclusion criteria were a known
syndrome or dysmorphic features, known chromosomal or genetic
abnormality, known severe chronic illness or endocrine disease
or positive gliadin, endomysial or reticulin antibodies, and severe
disproportionate short stature.
All children were evaluated at baseline and every 3 months during
rhGH treatment. Evaluations included measurements of weight
(using a digital scale), standing height (standing height was the
mean of three measurements with a Harpenden stadiometer) and
pubertal status graded according to Marshall and Tanner.
 
10,11
 
 One
hundred and ninety children were treated for 2 years. The phenotypic
characteristics are presented in Table 1. The sex ratio was 138 boys
to 102 girls with a mean birth length of –2·9 ± 1·4 SDS and birth-
weight of –2·3 ± 1·0 SDS. Mean maternal height was –1·0 ± 1·3 SDS
and mean paternal height –0·8 ± 1·0 SDS. Age at onset of rhGH
treatment was 6·6 ± 2·3 years with a mean height of 
 
–
 
3·0 ± 0·7 SDS
and a mean weight of 
 
–
 
2·4 ± 0·9 SDS. The mean rhGH dose was
0·4 ± 0·17 mg/kg/week. Forty-three patients received a replacement
rhGH dose (0·21 ± 0·04 mg/kg/week) while the majority of children
(
 
n
 
 = 197) received a higher dose of rhGH (0·43 ± 0·17 mg/kg/week).
 
Growth prediction
 
For each child, a growth prediction for the first year of therapy
was calculated according to Ranke 
 
et al
 
.
 
2
 
 The prediction model
incorporates rhGH dose, age and weight at start of therapy (given
in SDS according to Freeman 
 
et al
 
.
 
12
 
) as well as gender-adjusted
midparental height (MPH) (in SGA) or the distance to MPH (given
in height SDS according to Tanner 
 
et al
 
.
 
13,14
 
) as the main prognostic
factors. The equation for prediction in short SGA children is: growth
during the first year (cm) = 9·4 + [56·51 
 
×
 
 rhGH dose (mg/kg/day)]
+ [
 
–
 
0·31 
 
×
 
 age at onset (years)] + [0·30 
 
×
 
 body weight SDS at start]
+ [0·11 
 
×
 
 MPH SDS].
The individual deviations from the prediction were divided by the
standard error of the prediction, which is 1·30 cm in SGA children,
 
2
 
resulting in the studentized residuals. A studentized residual of 0
means that the prediction was completely fulfilled. Positive values
indicate growth exceeding the prediction, negative values are the
expression of growth slower than predicted.
 
Controls
 
The controls were of white Caucasian descent and were recruited
in early to mid-adulthood according to a standard protocol, where
auxological details (birth length, birthweight, gestational age, current
weight and height, blood pressure, current medical history and
medication) were recorded and a blood sample was drawn for DNA
extraction.
 
Molecular studies
 
Genomic DNA was isolated from peripheral blood leucocytes
by standard methods from all patients. The frequency of the GHR
transcript variant [full-length (fl) or exon 3 deleted (d3)] was tested
in all subjects using a simple multiplex polymerase chain reaction
(PCR) assay described by Pantel 
 
et al
 
.
 
4
 
 Amplification products were
analysed by electrophoresis on a 1% agarose gel stained with ethidium
bromide. The fl-GHR is represented by a 935-bp fragment and the
d3-GHR by a 532-bp fragment.
 
Statistical analysis
 
Qualitative variables are listed as frequencies and percentages,
whereas quantitative variables are shown as mean ± SD, or median and
range. Patients were divided by genotype and compared with regard
to continuous parameters (e.g. age, midparental height in SDS, height
at start of treatment in SDS, birth length and birthweight in SDS,
paternal and maternal height in SDS), as well as changes in height
velocity.
Table 1. Phenotype and genotype of NESTEGG short SGA (n = 240) and 
controls (n = 193). Data are presented as mean ± SD or percentage
SGA 
(n = 240)
Controls 
(n = 193)
Phenotype
Sex ratio (M/F) 138/102
Birth length (SDS) –2·9 ± 1·4
Birthweight (SDS) –2·3 ± 1·0
Maternal height (SDS) –1·0 ± 1·3
Paternal height (SDS) –0·8 ± 1·0
Age at onset of GH treatment (years) 6·6 ± 2·3
Height at start of GH treatment (SDS) –3·0 ± 0·7
Weight at start of GH treatment (SDS) –2·4 ± 0·9
GH dose (mg/kg/week) 0·40 ± 0·17
Genotype
fl/fl, % (n) 60 (144) 51 (98)
fl/d3, % (n) 27 (65) 41 (80)
d3/d3, % (n) 13 (31) 8 (15)
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The response to rhGH was evaluated by annual growth velocities
(in cm/year) and by the differences between growth velocity before
GH treatment and during the first and/or second year of GH treat-
ment as published.
 
6,7
 
 Height velocity expressed in SDS was not chosen
as all children were prepubertal and there was no sex difference
at this age.
The d3/d3 and d3/fl patients were grouped together (group D) to
compare them with patients with the fl/fl genotype.
Comparisons between groups were made by the Mann–Whitney
test or the Kruskall–Wallis test, as appropriate. A 
 
P
 
-value of less than
0·05 was considered statistically significant. All statistical analyses
were performed with Statview for Windows.
 
Results
 
Distribution of d3-GHR and fl-GHR
 
The calculated allele frequencies were 73·5% for fl-GHR 
 
vs.
 
 26·5%
for d3-GHR in the SGA population and 73% 
 
vs.
 
 27% in the controls.
Table 1 shows the distribution of the genotypes in the SGA children
and in the controls.
 
GHR exon 3 genotypes and clinical characteristics
 
In the SGA children, the mean birthweight in SDS was significantly
lower in the d3/d3 group than in the two other groups: 
 
–
 
2·6 ± 0·7
SDS 
 
vs.
 
 
 
–
 
2·2 ± 0·9 SDS in the fl/d3 group (
 
P = 
 
0·016) and 
 
–
 
2·2 ± 0·7
SDS in the fl/fl group (
 
P = 
 
0·034). This difference was not present
in the control population: 
 
–
 
0·5 ± 0·8 SDS in the d3/d3 group 
 
vs.
 
–
 
0·3 ± 1·0 in the fl/d3 group and 
 
–
 
0·4 ± 1·0 in the fl/fl group.
There was no significant difference in birth length, age, height and
weight at start of GH treatment, parental heights and spontaneous
height velocity between the three different genotype groups.
 
GHR exon 3 genotypes and response to rhGH in short SGA 
children
 
The change in height velocity during the first and the second year
was not significantly different between the three groups. However,
the combined group of d3/d3 and d3/fl children (group D) showed
a significantly higher change of growth velocity during the first year
(
 
P = 
 
0·038, Fig. 1), second year (0·041) and both years (
 
P = 
 
0·03).
Data are shown in detail in Table 2.
When we divided the children into two groups according to rhGH
dose [high dose (
 
n
 
 = 197) and low dose (
 
n
 
 = 43)], a significant
change in growth velocity during the first year was observed in the
high-dose group (
 
P = 
 
0·027) but not in the low-dose group (Fig. 1).
Studentized residuals in the fl/fl group were significantly lower
(
 
P = 
 
0·04), meaning that these children grew less than predicted,
while they was no significant difference in the other two groups
(Fig. 2).
 
Discussion
 
We took the opportunity of the NESTEGG project to analyse a
subgroup of this population with prepubertal short SGA children
treated with rhGH for 1 or 2 years.
Fig. 1 Change in growth velocity during the first year of GH treatment in 
the 240 SGA children according to the dose of rhGH: high dose 
0·43 ± 0·17 mg/kg/week; low dose 0·21 ± 0·04 mg/kg/week. Results are 
presented as boxes with the horizontal line inside the box representing the 
mean and the vertical line representing the interquartile range (10th–90th 
centiles). The extreme values are presented as circles. The d3/d3 + fl/d3 group 
(or D group) is in white and the fl/fl group is in grey.
Table 2. Growth velocities (cm/year) and changes in growth velocities before and during the first 2 years of GH treatment. Data are presented as median (range)
d3/d3 
(n = 31)
fl/d3 
(n = 65)
fl/fl 
(n = 144)
(fl/d3 + d3/d3) 
or D (n = 96)
GV0 5·3 (3·0–11·0) 5·4 (2·0–11·2) 5·6 (0·8–13·1) 5·3 (2·0–11·2)
GV1 9·9 (5·8–13·5) 9·3 (5·9–14·3) 9·3 (4·9–15·0) 9·6 (5·8–14·3)
GV2 7·5 (4·0–10·6) 8·0 (5·3–12·1) 7·7 (3·6–10·8) 7·9 (4·0–12·1)
(GV1 + GV2)/2 9·1 (4·9–12·0) 8·8 (6·7–13·2) 8·7 (4·9–12·3) 8·9 (4·9–13·2)
∆(GV1 – GV0) 4·4 (–3·6 to 8·4) 4·1 (–1·4 to 7·6) 3·7 (–5·1 to 10·0) 4·2 (–3·6 to 8·4)*
∆(GV2 – GV0) 2·5 (–1·8 to 6·0) 2·6 (–2·7 to 7·0) 2·1 (–6·1 to 7·4) 2·6 (–2·7 to 7·0)†
∆[(GV1 + GV2)/2 – GV0] 3·4 (–0·3 to 6·9) 3·2 (–1·9 to 6·4) 2·8 (–4·6 to 8·5) 3·2 (–1·9 to 6·9)‡
Studentized residuals GV1 0·25 (–2·8 to 2·2) 0·02 (–2·5 to 3·5) –0·20 (–3·6 to 2·8)§ 0·03 (–2·8 to 3·5)
D, the combination of the two groups fl/d3 and d3/d3; GV0, growth velocity before GH treatment; GV1, growth velocity during the first year of GH treatment; 
GV2, growth velocity during the second year of GH treatment; (GV1 + GV2)/2, mean growth velocity during the first 2 years of GH treatment.
*P = 0·038 between fl/fl and D groups. †P = 0·041 between fl/fl and D groups. ‡P = 0·03 between fl/fl and D groups. §P = 0·04 indicates significant difference 
between observed and predicted growth velocity using the SGA prediction model.
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This study, of a large multinational cohort of short SGA children,
is unique and showed the association of the exon 3 GHR poly-
morphism with rhGH responsiveness in the largest population reported
so far. In the first study,
 
6
 
 performed in France, SGA children represented
35% of the study population (60 SGA among 172 short children).
Another study was performed in Germany in 60 SGA children.
 
7
 
In both studies the exon 3 GHR polymorphism was associated
with rhGH responsiveness. Conversely, a more recent publication
did not report any significant difference in GH responsiveness in
a large Spanish population of 170 SGA children and adolescents.
 
8
 
We did not find a significantly higher growth velocity in the d3/d3
group as published.
 
7
 
 Nevertheless, we did find a significant larger
change in growth velocity, only in the mixed group of homozygotes
and heterozygotes, during the first year and the first 2 years of GH
treatment in this population of short SGA children, as reported in
the first study.
 
6
 
 This suggests the involvement of other factors. In
another study combining different populations with short stature
 
7
 
(Turner and SGA), the effect of this polymorphism in short SGA
children was lower than in GH-deficient
 
15
 
 or Turner
 
7
 
 children in
terms of growth velocity. The influence of the exon 3 GHR poly-
morphism in SGA became more evident when growth was analysed
by the SGA growth prediction model, which takes into consideration
the variability of the response to treatment between individuals. The
magnitude of the difference is small but in the same range as in the
previous publication.
 
7
 
In our study, the association of the exon 3 GHR polymorphism
with growth responsiveness was observed in the group with the
higher rhGH dose (0·43 ± 0·17 mg/kg/week). The lack of signifi-
cance in the group with a lower dose could be due to the small
number of children (43 
 
vs.
 
 197).
Discordant results regarding the exon 3 GHR polymorphism
and rhGH responsiveness have also been reported a in GH-
deficient population.
 
15,16
 
 The NESTEGG cohort is a multinational
cohort, which could reduce the effect of specific population
polymorphisms. The distribution of the three genotypes is not
significantly different in this study compared to the different reports
in Caucasian populations.
 
6,7,16
 
In our study, the frequency of the d3-GHR variant was comparable
in the SGA and in the controls, suggesting that this polymorphism
is not primarily related to the genesis of SGA. However, a recent
publication
 
17
 
 performed in a Spanish population reported a significantly
higher frequency of the fl/fl genotype in SGA compared to controls.
In our study, birthweight was significantly lower in the d3/d3
group, while this difference was not observed in the controls. As the
expression of the GHR is low before birth, it is unlikely that this
difference is due to the exon 3 GHR polymorphism.
Our data, based on a large cohort, showed that the exon 3 GHR
polymorphism is associated with the responsiveness to rhGH treat-
ment in SGA children with short stature. However, given the
contradictory findings in other reports, this polymorphism is probably
not a major factor among those influencing GH response.
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